反应详情

To a solution of (R)-5-methyl-4-((S)-2-methylpiperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine dihydrochloride (prepared according to Example 3, Steps 1 and 2; 32 mg, 0.14 mmol) in DCM (5 mL) were added triethylamine (1 mL), 3-((tert-butoxycarbonylamino)-2-(4-chloro-3-fluorobenzyl)propanoic acid (46 mg, 0.14 mmol) and HBTU (52 mg, 0.14 mmol). The mixture was stirred at room temperature for 1 hour. The solvent was removed and the residue was purified by silica gel chromatography, eluting with ethyl acetate to afford tert-butyl 2-(4-chloro-3-fluorobenzyl)-3-((S)-3-methyl-4-((R)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropylcarbamate (50 mg, 72%). 1H NMR (CDCl3, 400 MHz) δ 8.44 (m, 1H), 7.28 (m, 1H), 7.05-6.80 (m, 2H), 5.10-4.90 (m, 1H), 4.70-4.30 (m, 1H), 4.10-3.70 (m, 1H), 3.40-3.20 (m, 2H), 3.00-2.80 (m, 2H), 2.20 (m, 1H), 1.70 (m, 1H), 1.43 (s, 9H), 1.25-0.70 (m, 6H). MS (APCI+) [M+H] +546.

1. customThe solvent was removed
2. customthe residue was purified by silica gel chromatography
3. washeluting with ethyl acetate